thalidomide has been researched along with dactolisib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Z; Li, J; Li, X; Liu, Z; Ouyang, Y; Qing, K; Wang, W; Xu, Z | 1 |
1 other study(ies) available for thalidomide and dactolisib
| Article | Year |
|---|---|
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinolines; Thalidomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |